Related Experiment Video

Updated: Mar 26, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.1K

[Cytoprotective Effects of Phytoestrogen Genistein against Cancer Cells]

T A Fedotcheva, K E Shirokih, A I Matyushin

    Biofizika
    |February 5, 2016
    PubMed

    Insights

    Synthetic isoflavonoid genistein exhibits a cytoprotective effect against HeLa cancer cells. It reduces the toxicity of common cancer drugs, indicating potential therapeutic benefits.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Pharmacology

    Context:

    • HeLa cells express estrogen receptors alpha but not beta.
    • Genistein's effects were compared to tamoxifen and cisplatin, standard cervical cancer treatments.
    • The study investigated genistein's impact on cancer cell viability and apoptosis.

    Purpose:

    • To determine if genistein has a cytotoxic or cytoprotective effect on HeLa cancer cells.
    • To evaluate genistein's potential to mitigate the side effects of chemotherapy drugs.
    • To elucidate the molecular mechanisms underlying genistein's action on cancer cells.

    Summary:

    • Genistein's IC50 for HeLa cell growth inhibition (0.2 mM) is significantly higher than tamoxifen and cisplatin.
    • At micromolar concentrations (0.1-10 μM), genistein reduced the cytotoxic effects of cisplatin and tamoxifen.
    • Genistein decreased Bax mRNA expression and increased Bcl-2 mRNA expression, indicating an anti-apoptotic effect.
    • Genistein did not affect mitochondrial membrane potential or calcium capacity, ruling out mitochondrial pore opening.

    Impact:

    • Genistein demonstrates a cytoprotective effect against HeLa cancer cells.
    • These findings suggest genistein could be a potential adjuvant therapy in cancer treatment.
    • Further research into genistein's anti-cancer properties is warranted.

    More Related Videos

    Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay06:07

    Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

    Published on: June 7, 2020

    5.4K
    Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

    Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

    Published on: June 9, 2023

    2.5K

    Related Concept Videos

    Cancer Prevention02:59

    Cancer Prevention

    Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
    Some...
    8.7K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.4K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    67
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.2K
    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    10.0K